Posted by Michael Wonder on 10 Jan 2017
AbbVie withdraws submission for Venclexta
10 January 2017 - Abbvie was seeking funding for venetoclax when used as a treatment for patients with chronic lymphocytic leukaemia who have received at least one prior therapy and have a 17p deletion.
AbbVie requested a voluntary withdrawal of the submission. As per pCODR procedures, the pCODR Provincial Advisory Group has agreed to the request to withdraw and decided to not continue the review as a PAG Submission. As per pCODR procedures, if a submission is withdrawn but a pERC initial recommendation has been made, the pCODR program will continue to post the pERC initial recommendation.
The pERC initial recommendation was to decline funding for the use of venetoclax in this patient population because it was not able to conclude it is associated with a net clinical benefit.
